

# The Neuro4D Conference 2024

Atrium Hotel Mainz – Mainz, Germany – Close to Frankfurt Airport



DEGENERATIVE  
DISEASE  
DRUG  
DISCOVERY

**MONDAY  
MAY 27<sup>TH</sup>**

<b>8:00</b>		
Registration and Joint Breakfast, attach Posters		
<b>8:30</b>		
Opening of the Conference: Andreas Köpke, bioExert		
<b>9:00</b>		
Common proteopathic neurodegenerative disease mechanisms <i>Chair: Janine Kutzsche , Research Center Jülich, Germany</i>		
<b>PANEL 09:30 – 10:30</b>		
ALS Disease Mechanism	How TDP43 reactivates endogenous retroviruses	<b>Roger Sher</b> Stony Brook University, USA
Enabling Technology	Longitudinal characterization of a transgenic B6.SOD1-G93A mutant based ALS mouse model	<b>Roland Rabl</b> QPS, Austria
ALS Disease Mechanism	Post-translational modifications driving TDP-43 phase separation and aggregation	<b>Philipp Kahle</b> U. Tübingen, Germany
Panel Q&A of Session Speakers <i>Chair: Janine Kutzsche , Research Center Jülich, Germany</i>		
<b>10:30 – 11:30</b>		
Coffee Break, Exhibition & Poster Viewing		
<b>PANEL 11:30 – 12:30</b>		
PD Disease Mechanism	A common gene expression signature in $\alpha$ -synuclein-based and other mouse models of Parkinson's disease	<b>Manuel Buttini</b> U. Luxembourg
Enabling Technology	Use of PFF and similar models of Parkinson's disease in preclinical drug testing	<b>Daniel Havas</b> Psychogenics, USA
PD Disease Mechanism	Classifying Parkinson's disease through biology	<b>Tiago Outeiro</b> U. Göttingen, Germany
Panel Q&A of Session Speakers <i>Chair: Janine Kutzsche , Research Center Jülich, Germany</i>		
<b>12:30</b>		
Lunch		

# The Neuro4D Conference 2024

Atrium Hotel Mainz – Mainz, Germany – Close to Frankfurt Airport



**MONDAY  
MAY 27<sup>TH</sup>**

<b>13:30</b>		
<b>New Therapeutic Options for Proteopathic Diseases</b>	ALS, FTLN, AD, and LATE, different diseases with similar treatment options?	<b>Neil Cashman</b> ProMIS, Canada
<b>PANEL 14:00 – 15:00</b>		
<b>AD New Treatment Strategies</b>	Targeting tau oligomerization as a therapeutic approach for AD and other tauopathies	<b>Joseph Rayman</b> Columbia University, USA
<b>Enabling Technology</b>	Assessment of functional deficits in preclinical animal studies	<b>Joseph Araujo</b> Intervivo Solutions, Canada
<b>AD New Treatment Strategies</b>	Nasal immunotherapy effectively clears intracellular tau pathology via TRIM21 and improves cognitive functions in a tauopathy mouse model	<b>Rakez Kaye</b> UTMB, USA
<b>Panel Q&amp;A of Session Speakers</b> <i>Chair: Neil Cashman, ProMIS, Canada</i>		
<b>15:00 – 17:00</b>		
<b>Coffee Break, Exhibition &amp; Poster Session</b> (All Presenters will be at their posters for discussion. Please vote for the best poster!) <b>One on One Meetings</b>		
<b>PANEL 17:00 – 18:00</b>		
<b>AD New Treatment Strategies</b>	Identification of deubiquitinating enzymes (DUBs) regulating seeded tau pathology: new therapeutic strategies for tauopathies?	<b>Christiane Volbracht</b> H. Lundbeck, Denmark
<b>PD New Treatment Strategies</b>	Structure-based vaccine candidates for Parkinson's disease	<b>Erdem Gültekin Tamgüney</b> Research Center Jülich, Germany
<b>AD Drug Discovery</b>	Characterization of amyloid- $\beta$ species in AD brain and the unique binding properties of Lecanemab	<b>Linda Söderberg</b> Bioartec, Schweden
<b>Panel Q&amp;A of Session Speakers</b> <i>Chair: Neil Cashman, ProMIS, Canada</i>		
<b>18:00</b>		
<b>Champagne Reception in the Foyer</b>		
<b>19:00 – 22:00</b>		
<b>Dinner</b> We will have a seated dinner, accompanied by fitting local wines. Depending on the weather, we will be on the hotel terrace, or in an adjacent room. There will be music by Julio Hierrezuelo and band again!		
<b>END OF THE FIRST DAY</b>		

# The Neuro4D Conference 2024

Atrium Hotel Mainz – Mainz, Germany – Close to Frankfurt Airport



DEGENERATIVE  
DISEASE  
DRUG  
DISCOVERY

**TUESDAY  
MAY 28<sup>TH</sup>**

<b>7:30</b>		
Joint Breakfast, Exhibition & Poster Viewing (Please vote for the best poster!)		
<b>8:30</b>		
<b>AD New Treatment Strategies</b>	Towards harnessing innate immunity targets to treat Alzheimer's disease	<b>Michael Heneka</b> U. Luxembourg
<b>PANEL 9:00 – 10:00</b>		
<b>HD Disease Mechanism</b>	Uncovering neurotoxic mechanisms of self-propagating huntingtin aggregates in Drosophila	<b>Erich Wanker</b> Max-Delbrück-Center, Berlin, Germany
<b>HD New Treatment Strategy</b>	Selective protein lowering strategies in Huntington's disease	<b>Eric Reits</b> U. Amsterdam, The Netherlands
<b>PD-Clinical Results</b>	The clinical failure of venglustat: should we now avoid targeting lysosomal pathways?	<b>Franziska Richter Assencio</b> U. of Veterinary Medicine Hannover, Germany
<b>Panel Q&amp;A of Session Speakers</b> Chair: Michael Heneka, U. Luxembourg		
<b>10:00 – 11:00</b>		
Coffee Break, Exhibition and Posters: Presenters are at the Poster to discuss (Final chance to rate the best poster!) Time for One on One Meetings		
<b>PANEL 11:00 – 12:00</b>		
<b>Enabling Technology</b>	Quantification of $\alpha$ -Syn oligomers in body liquids	<b>Oliver Bannach</b> Attyloid, Germany
<b>AD Biomarker</b>	CSF A $\beta$ oligomers peak in early clinical stages of Alzheimer's disease and precede tau pathology	<b>Dieter Wilbold</b> Heinrich-Heine -University, Germany
<b>AD – Implications for Transfer of Clinical Material</b>	Iatrogenic Alzheimer's disease in recipients of cadaveric pituitary-derived growth hormone	<b>Tzehow Mok</b> MRC Prion Unit, London, UK
<b>Panel Q&amp;A of Session Speakers</b> Chair: Michael Heneka, U. Luxembourg		
<b>12:00</b>		
Lunch		

# The Neuro4D Conference 2024

Atrium Hotel Mainz – Mainz, Germany – Close to Frankfurt Airport



**TUESDAY  
MAY 28<sup>TH</sup>**

<b>13:00</b>		
Clinical Studies in Neurodegenerative Diseases	Biomarker-based disease modification in preclinical stages of Alzheimer's disease	<b>Oliver Peters</b> Psychiatric Clinic Frankfurt Oder, Germany
<b>PANEL 13:30 – 14:30</b>		
PD Clinical Trial	Lu AF82422, a human monoclonal antibody against $\alpha$ -synuclein for the treatment of $\alpha$ -synucleinopathies, selected based on epitope and potency in $\alpha$ -synuclein seeding models	<b>Pekka Kallunki</b> H. Lundbeck, Denmark
Clinical Trial	How a diabetes drug may hold promise for early Alzheimer's: Insights from the EVOKE trials	<b>Sebastian Meyhöfer</b> Novo Nordisk, Germany
PD Clinical Trial	Safety, tolerability and pharmacokinetics in healthy volunteers after administration of exidavnemab, a high affinity and high selectivity antibody targeting toxic aggregates of $\alpha$ -synuclein	<b>Emma Boström</b> Bioarttic, Sweden
<b>Panel Q&amp;A of Session Speakers</b> <i>Chair: Oliver Peters, Psychiatric Clinic Frankfurt Oder, Germany</i>		
<b>14:30</b>		
Coffee Break & Final Poster Session		
<b>15:30</b>		
<b>Panel Discussion:</b>		
<ul style="list-style-type: none"><li>• How much more evidence do we need before the prion-like disease mechanism is finally generally accepted and communicated?</li><li>• Prevention and treatment of neurodegeneration: Finally, selected A<math>\beta</math>-antibodies work, but which possible modes of action offer more affordable therapy against a prion-like disease mechanism in the future?</li><li>• What influence does life style and BMI really have on neurodegenerative disease progression?</li></ul>		
<b>Panel Participants:</b>		
Oliver Peters	Clinic for Psychiatry and Psychotherapy, Frankfurt Oder, Germany	
Sebastian Meyhöfer	Novo Nordisk, Germany	
Neil Cashman	ProMIS, Vancouver, Canada	
<b>Moderator: Andreas Köpke, bioExpert</b>		
<b>16:15</b>		
<b>Price for the Best Poster</b> <i>'Scientific progress towards improving the life of patients and their families' presented at the International Neuro4D Conference 2024</i>		
<b>16:25</b>		
Summary and wrap-up of the conference		
<b>16:30</b>		
<b>END OF THE CONFERENCE AND DEPARTURE</b>		